Older patients with higher-risk myelodysplastic syndromes who received early stem cell transplantation and reduced-intensity chemotherapy survived longer than those who did not receive transplants, a study found. Researchers also said older patients with lower-risk MDS should not get early stem cell transplantation unless their quality of life is considerably diminished.

Full Story:

Related Summaries